Compounds > 3-acryloyloxypropionic acid
Page last updated: 2024-11-06

3-acryloyloxypropionic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-acryloyloxypropionic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID90558
CHEMBL ID3185107
SCHEMBL ID27385
MeSH IDM0158088

Synonyms (53)

Synonym
beta-(acryloyloxy)propionic acid
3-acryloyloxypropionic acid
hydracrylic acid, acrylate
sipomer b-cea
einecs 246-359-9
beta-carboxyethyl acrylate
2-carboxyethyl 2-propenoate
2-carboxyethyl acrylate
2-carboxyethyl acrylate, contains 900-1100 ppm mehq as inhibitor
24615-84-7
3-(acryloyloxy)propanoic acid
2-propenoic acid, 2-carboxyethyl ester
AKOS006377408
3-prop-2-enoyloxypropanoic acid
NCGC00249195-01
hydracrylic acid acrylate
unii-km1e1216wr
km1e1216wr ,
tox21_303489
dtxsid2027834 ,
dtxcid807834
cas-24615-84-7
NCGC00257334-01
tox21_202236
NCGC00259785-01
ebecryl .beta.-cea
.beta.-hydroxypropionic acid acrylic ester
.beta.-(acryloyloxy)propionic acid
carboxyethyl acrylate
acrylic acid dimer
carboxyethyl acrylate [inci]
aronix m 566
c 800 (acrylate)
acrylic acid 2-carboxyethyl ester
3-(acryloyloxy)propionic acid
SCHEMBL27385
beta-carboxyethylacrylate
beta-acryloxypropionic acid
CYUZOYPRAQASLN-UHFFFAOYSA-N
beta carboxyethyl acrylate
W-110598
CHEMBL3185107
FT-0698084
7bc ,
beta-carboxyethyl acrylate,distribution
2-carboxyethylacrylate
Q27282330
CS-0346107
ZAA61584
EN300-202121
3-(prop-2-enoyloxy)propanoic acid
AS-77136
F71247
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency82.32100.002541.796015,848.9004AID1347395
GLI family zinc finger 3Homo sapiens (human)Potency1.26020.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency64.07370.000221.22318,912.5098AID1259247; AID743035; AID743042; AID743053; AID743054; AID743063
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency36.25030.001022.650876.6163AID1224838; AID1224839; AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency47.11520.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency79.51080.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency54.94100.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency70.58410.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency61.64480.375827.485161.6524AID743217
estrogen nuclear receptor alphaHomo sapiens (human)Potency61.39650.000229.305416,493.5996AID743091
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency56.76210.001019.414170.9645AID743094; AID743140
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency76.95880.001723.839378.1014AID743083
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency9.20180.000627.21521,122.0200AID743202; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (11.11)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's4 (44.44)24.3611
2020's3 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.82 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
1-anilino-8-naphthalenesulfonate
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd. 8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.		2.2110aminonaphthalene;
naphthalenesulfonic acid		fluorescent probe
methylene blue
Methylene Blue: A compound consisting of dark green crystals or crystalline powder, having a bronze-like luster. Solutions in water or alcohol have a deep blue color. Methylene blue is used as a bacteriologic stain and as an indicator. It inhibits GUANYLATE CYCLASE, and has been used to treat cyanide poisoning and to lower levels of METHEMOGLOBIN.. methylene blue : An organic chloride salt having 3,7-bis(dimethylamino)phenothiazin-5-ium as the counterion. A commonly used dye that also exhibits antioxidant, antimalarial, antidepressant and cardioprotective properties.		2.610organic chloride saltacid-base indicator;
antidepressant;
antimalarial;
antimicrobial agent;
antioxidant;
cardioprotective agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 4.6.1.2 (guanylate cyclase) inhibitor;
fluorochrome;
histological dye;
neuroprotective agent;
physical tracer
acrylamide
[no description available]		2.110acrylamides;
N-acylammonia;
primary carboxamide		alkylating agent;
carcinogenic agent;
Maillard reaction product;
mutagen;
neurotoxin
ethylene dimethacrylate
ethylene glycol dimethacrylate : The enoate ester that is the 1,2-bis(methacryloyl) derivative of ethylene glycol.		2.3110enoate esterallergen;
cross-linking reagent;
polymerisation monomer
triethylene glycol dimethacrylate
[no description available]		2.0810
zinc oxide
Zinc Oxide: A mild astringent and topical protectant with some antiseptic action. It is also used in bandages, pastes, ointments, dental cements, and as a sunblock.		1.9710zinc molecular entity
2-(dimethylamino)ethyl methacrylate
2-(dimethylamino)ethyl methacrylate: reducing agent; structure given in first source		2.2110
fibrinogen
Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.. D-iditol : The D-enantiomer of iditol.		2.5320iditolfungal metabolite
chitosan
[no description available]		2.0310
ConditionIndicatedRelationship StrengthStudiesTrials
Glial Cell Tumors
[description not available]		02.110
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		02.110